ENG

LOS ANGELES, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced today that John S. Yu, M.D., Chief Executive Officer, will present a corporate overview at the LD Micro Main Event XVII. The conference is being held on October 28 – 30, 2024 at the Luxe Sunset Boulevard Hotel in Los Angeles. Event:LD Micro Main Event XVIIPresentation Date:Wednesday, October 30, 2024Time:12:00 PM PTRegister to watch presentation:https://me24.sequireevents.com/ About Kairos Pharma Ltd. Based in Los Angeles, California, Kairos Pharma Ltd. (NYSE American: KAPA) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Our lead candidate, ENV105, is an antibody that targets CD105—a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy results in resistance and disease relapse. ENV105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is in a Phase 2 clinical trial for castrate resistant prostate cancer and a Phase 1 trial for lung cancer, addressing significant unmet medical needs. For more information, visit kairospharma.com. CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements as those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential” or “hopes” or the negative of these or similar terms. The reader is cautioned not to rely on these forward-looking statements. If underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kairos Pharma. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including: our expectations regarding the success and/or completion of our Phase 1 and Phase 2 clinical trials; our success in completing newly initiated clinical trials, commence new trials, and obtain regulatory approval following the conclusion of such trials; challenges and uncertainties inherent in product research and development; and the uncertainty regarding future commercial success. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking statements discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us, including those described in Kairos Pharma’s prospectus filed with the SEC. We are not obligated to publicly update or revise any forward-looking statement, and Kairos Pharma is not required to update any forward-looking statement as a result of new information or future events or developments, except as required by U.S. federal securities laws. Contact: CORE IRLouie Tomainvestors@kairospharma.com

Diagonal is advancing its lead program to treat the underlying cause of hereditary hemorrhagic telangiectasia (HHT)WATERTOWN, Mass., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company pioneering a new approach to discovering and developing agonist antibodies, today announced they will participate in multiple presentations at Cure HHT’s upcoming 15th HHT International Scientific Conference, taking place in Mandelieu-la-Napoule, France, October 15-19th, 2024. HHT is a severely debilitating bleeding disorder caused by mutations in ALK1 or Endoglin genes. These mutations lead to severe nosebleeds and gastrointestinal bleeds that lead to transfusion-dependent anemia. People with HHT are also at risk for life-threatening arteriovenous malformation (AVM) ruptures in critical organs such as the liver, lungs, and brain. The disease affects roughly 150,000 people in the United States and European Union. “We’re grateful to Cure HHT for inviting us to speak at their 15th annual meeting, which focuses on advancements in HHT research and emerging therapeutic options for patients. The need for better treatment options is evident, and we are pleased to be able to provide an update on our lead program," said Alex Lugovskoy, Ph.D., Chief Executive Officer of Diagonal. “While still early, our ALK1 agonist antibody, designed specifically for people with HHT, has demonstrated the ability to prevent and reverse the formation of AVMs in two HHT-relevant in vivo models and restored normal signaling in patient-derived cells. We hope these data can translate to significant patient benefit in the clinic." Details on the presentations are as follows: Poster: Bispecific antibodies targeting the ENG-ALK1-BMPRII axis as a novel approach for the treatment of HHT Presenter: JC Hus, Ph.D., Senior Director, Informatics, Diagonal Therapeutics Invited Talk: Therapeutic Potential of ALK1 Activating Drugs in HHT Models Presenter: Philippe Marambaud, Ph.D., Professor, Institute of Molecular Medicine, Feinstein Institutes for Medical Research and Diagonal Therapeutics scientific collaborator Invited Talk: Advancing a New Approach to Tackle the Root Cause of HHT Presenter: Eric Duhaime, SVP, Finance and Corporate Development, Diagonal Therapeutics About Hereditary Hemorrhagic Telangiectasia (HHT) HHT is a rare disease that affects more than 150,000 people in the US and EU, and for which there are currently no approved therapies. In HHT, mutations in the TGF-β receptor superfamily complex create two types of abnormal blood vessels – telangiectasias and arteriovenous malformations (AVMs) – that are fragile and susceptible to rupture and bleeding. These bleeding events lead to chronic anemia, necessitating frequent iron infusions or red blood cell transfusions. AVMs, if left untreated, may result in lung and brain hemorrhage, stroke, heart failure, and death. Diagonal’s agonist antibody candidates reactivate dormant signaling, addressing the root cause of the disease. About Diagonal TherapeuticsDiagonal Therapeutics is a biotech company pioneering a new approach to discovering and developing agonist antibodies. The Company's DIAGONAL platform combines proprietary computational and experimental techniques to overcome historical challenges associated with agonist antibody drug discovery. Diagonal's emerging pipeline – discovered using the DIAGONAL platform – has the potential to deliver life-changing therapies to patients by tackling the underlying cause of disease. For more information, please visit www.diagonaltx.com.Media Contact:Cory Trombleemedia@diagonaltx.com

Kairos Pharma’s stock had a bumpy ride on its first day trading, shedding 35% of its value to end Monday down at $2.60. With a trio of biotechs hitting the Nasdaq on Friday, it was easy to miss a smaller-scale public debut from another clinical-stage drug developer on the other side of the European Society of Medical Oncology annual meeting this weekend.Unlike last week’s nine-figure offerings, Kairos Pharma’s IPO brought in a more modest $6.2 million yesterday. The Los Angeles-based biotech—whose stock listed on the NYSE under the ticker “KAPA” Sept. 16—sold 1.55 million shares at $4 apiece.Underwriters have 45 days to buy an additional 232,500 shares at the same price, which could bring in another $930,000, the company explained in a Sept. 16 release.The top priority for spending the IPO proceeds is the biotech’s lead candidate ENV 105, an endoglin-targeting monoclonal antibody that the company said is designed to “reverse resistance to standard-of-care drugs.”Kairos is already assessing ENV 105 in a phase 1 trial for non-small cell lung cancer in combination with AstraZeneca’s Tagrisso, as well as a phase 2 prostate cancer study in combination with Johnson & Johnson’s Erleada. Behind ENV 105 are preclinical candidates like KROS 101, a small molecule agonist for the GITR ligand, which is designed to promote T cell growth and cytotoxic function against cancer.  There’s also ENV 205, an antibody that targets mitochondrial DNA that’s elevated as patients become resistant to chemotherapies.Kairos' stock had a bumpy ride on its first day of trading, shedding 35% of its value to end Monday down at $2.60.It’s a stark contrast to the three biotech Nasdaq IPOs on Friday, which all experienced a warmer reception on the public markets. Bicara Therapeutics' $315 million offering was the largest IPO of the day, and the company saw its $18 debut share price jump 41% to $25.41 by close of trading Monday. Meanwhile, MBX was trading up 26% at $21.65, and Zenas BioPharma was trading up 5% at $17.90 by the same point.Kairos launched as a spinout from the Cedars-Sinai Medical Center in 2013 before merging with AcTcell Biopharma in 2019. Two years later, the biotech also absorbed Enviro Therapeutics, which had been developing ENV 105.